Abstract
This study provides a high-resolution anatomical roadmap of the nerves surrounding the human common hepatic artery (CHA) to guide catheter-based sympathetic denervation, a potential treatment for Type 2 Diabetes (T2D). By analyzing over 11,000 nerves from 20 cadaveric donors, researchers identified the proximal segment of the CHA as the optimal target for ablation. Nerve abundance was found to be highest near the aortic ostium and significantly greater in the superior and inferior quadrants. Crucially, the pancreas—a sensitive non-target organ—is furthest from the artery in this proximal region. These findings offer critical morphometric data for the design of safe and effective denervation devices, accounting for variations in sex and diabetic status.
Introduction
Type 2 Diabetes (T2D) management is often complicated by poor patient adherence to daily medication. Consequently, clinical interest has shifted toward procedural interventions, specifically sympathetic denervation. Overactivity in the sympathetic nervous system is a known contributor to insulin resistance. By using a catheter to deliver radiofrequency or ultrasound energy to nerves surrounding the hepatic arteries, clinicians aim to "reset" metabolic signaling.
Lessons from early failures in renal denervation highlighted a critical gap: catheters must be designed with a precise understanding of target nerve locations. This study addresses that gap by providing foundational morphometric data for the human common hepatic artery (CHA), ensuring future hepatic denervation devices are both safe and effective.
Methods and Materials
The research team conducted a digital morphometry study on 20 human cadaveric donors (11 diabetic, 9 non-diabetic), aged 48 to 78.
- Histology: CHA samples were collected and processed using Hematoxylin and Eosin (H&E) staining for general anatomy and Tyrosine Hydroxylase (TH) staining to specifically identify sympathetic nerves.
- Digital Mapping: Using Fiji and MATLAB, the team quantified the size, number, and exact radial/circumferential positions of 11,000+ nerves.
- Safety Analysis: Researchers also mapped "non-target" structures, including the pancreas, lymph nodes (LN), and adjacent veins, to determine safe ablation buffers.
Key Anatomical Insights
The Proximal "Sweet Spot"
Nerve abundance is highest near the aorta (the ostium) and decreases significantly as the artery moves toward the liver (P < 0.0001). Simultaneously, the pancreas is furthest away in this proximal region (rarely within 4 mm of the lumen). This makes the proximal CHA the safest and most effective zone for treatment.
Nerve Distribution and Depth
Nerves are not distributed uniformly; they are significantly more abundant in the Superior and Inferior quadrants compared to the Anterior and Posterior ones (P = 0.014). On average, 81.6 nerves per section were identified—roughly double the density found in renal arteries. The median nerve distance from the lumen was 2.75 mm, though some nerves were located as deep as 6.5 mm.
Impact of Diabetes and Sex
In diabetic donors, nerves were 28% larger in cross-sectional area than in non-diabetics. This suggests that larger nerve bundles in diabetic patients may require adjusted energy doses for successful ablation. Additionally, males tended to have approximately 10% more nerves than females, with nerves located slightly further from the artery lumen.
Discussion and Limitations
While this study provides a robust roadmap, several factors must be considered for clinical translation. Standard histological processing causes tissue shrinkage of 20–30%, meaning the distances measured likely underestimate those in living patients. Furthermore, while the dataset of 11,000 nerves is extensive, the cohort of 20 donors is relatively small for establishing broad demographic trends.
Conclusion
The human common hepatic artery is a rich and accessible target for sympathetic denervation. The data indicate that efficacy and safety are most optimally balanced in the proximal segment of the artery. These findings are currently informing the design of clinical trials, such as the DeLIVER study, and the refinement of next-generation denervation catheters.
Summary updated